Accessibility Menu
TG Therapeutics logo

TG Therapeutics

(NASDAQ) TGTX

Current Price$36.62
Market Cap$5.73B
Since IPO (2011)+3,192%
5 Year+9%
1 Year+7%
1 Month+11%

TG Therapeutics Financials at a Glance

Market Cap

$5.73B

Revenue (TTM)

$700.35M

Net Income (TTM)

$461.90M

EPS (TTM)

$2.87

P/E Ratio

13.04

Dividend

$0.00

Beta (Volatility)

1.84 (High)

Price

$36.62

Volume

1,528,302.998

Open

$36.85

Previous Close

$36.64

Daily Range

$36.48 - $37.29

52-Week Range

$25.28 - $44.65

TGTX: Motley Fool Moneyball Superscore

71

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TG Therapeutics

Industry

Biotechnology

Employees

399

CEO

Michael Sean Weiss

Headquarters

Morrisville, NY 10014, US

TGTX Financials

Key Financial Metrics (TTM)

Gross Margin

83%

Operating Margin

21%

Net Income Margin

66%

Return on Equity

113%

Return on Capital

11%

Return on Assets

30%

Earnings Yield

7.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.73B

Shares Outstanding

153.08M

Volume

1.53M

Avg. Volume

2.03M

Financials (TTM)

Gross Profit

$515.57M

Operating Income

$123.32M

EBITDA

$134.36M

Operating Cash Flow

-$24.77M

Capital Expenditure

-$214.00K

Free Cash Flow

-$24.99M

Cash & ST Invst.

$141.97M

Total Debt

$260.73M

TG Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$204.92M

+69.6%

Gross Profit

$171.41M

+62.8%

Gross Margin

83.65%

N/A

Market Cap

$5.73B

N/A

Market Cap/Employee

$16.27M

N/A

Employees

352

N/A

Net Income

$19.78M

+290.8%

EBITDA

$34.80M

+183.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

-$239.13M

-1161.3%

Accounts Receivable

$392.05M

+106.2%

Inventory

$129.03M

-18.2%

Long Term Debt

$751.74M

+197.6%

Short Term Debt

$1.82M

+63.3%

Return on Assets

30.21%

N/A

Return on Invested Capital

11.14%

N/A

Free Cash Flow

-$17.95M

+37.6%

Operating Cash Flow

-$17.89M

+37.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PTCTPTC Therapeutics, Inc.
$68.23-7.55%
KYMRKymera Therapeutics, Inc.
$71.29-9.15%
PTGXProtagonist Therapeutics, Inc.
$93.23-1.78%
IMVTImmunovant, Inc.
$30.92-5.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
MRVLMarvell Technology
$290.79+0.33%
ONDSOndas
$13.58+0.01%
SOFISoFi Technologies
$17.74-0.05%
IBITiShares Bitcoin Trust
$38.05-0.06%

Questions About TGTX

What is the current price of TG Therapeutics?

TG Therapeutics is trading at $36.64 per share.

What is the 52-week range for TG Therapeutics?

Over the past 52 weeks, TG Therapeutics has traded between $25.28 and $44.65.

How much debt does TG Therapeutics have?

As of the most recent reporting period, TG Therapeutics reported total debt of $753.56M.

How much cash does TG Therapeutics have on hand?

TG Therapeutics reported $442.21M in cash and cash equivalents in its most recent financial results.

What is TG Therapeutics’s dividend yield?

TG Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.